Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Amarna Therapeutics and NorthX Biologics Finalize Agreement to Advance Nimvec™ AM510 Gene Therapy for Type 1 Diabetes.
Jul 09, 2025
Contract Type
agreement
LeidenManufacturingBiotechnologyHealth CareScience And EngineeringBiopharma
Description
Amarna Therapeutics has formalized an agreement with NorthX Biologics to advance Nimvec™ AM510 toward clinical trials focused on Type 1 Diabetes. The agreement aims to fast-track development activities necessary for cGMP manufacturing and clinical readiness.
Quick answer
Amarna Therapeutics and NorthX Biologics Finalize Agreement to Advance Nimvec™ AM510 Gene Therapy for Type 1 Diabetes. (July 9, 2025). Amarna Therapeutics is based in Leiden, South Holland, Netherlands.
What agreement did Amarna Therapeutics announce on July 9, 2025?
Amarna Therapeutics has formalized an agreement with NorthX Biologics to advance Nimvec™ AM510 toward clinical trials focused on Type 1 Diabetes. The agreement aims to fast-track development activities necessary for cGMP manufacturing and clinical readiness.
What does Amarna Therapeutics do?
Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of rare and prevalent diseases.
Where is Amarna Therapeutics based?
Amarna Therapeutics is based in Leiden, South Holland, Netherlands.
Source: Fundz verified event record.
Company Information
Company
Amarna Therapeutics
Location
Leiden, South Holland, Netherlands
About
Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero) that for the first time makes it possible to produce SV40-derived vectors suitable for therapeutic use. The company's fully integrated gene therapy platform combining SuperVero with its genetically engineered SVec viral vector is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this 'natural' non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation. Founded in 2008, Amarna's head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.